Luciano Costa: CC-93269 Shows Clinical Activity in Previously Treated Myeloma
Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T...
Deepu Madduri: An Emerging CAR T-Cell Therapy for Myeloma
Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and...
FDA Approves Daratumumab-Based Quadruplet Regimen for Transplant-Eligible Myeloma
The U.S. Food and Drug Administration (FDA) approved the quadruplet regimen consisting of daratumumab, bortezomib, thalidomide, and dexamethasone to treat adult patients with newly...
Carfilzomib-Based Quadruplet Regimen Beats Triplet Approach in Newly Diagnosed Myeloma
Induction with the quadruplet regimen of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) led to deeper responses and longer progression-free survival (PFS) in patients with...
Subcutaneous and Intravenous Daratumumab Have Similar Safety, Efficacy in Previously Treated and Newly Diagnosed...
A subcutaneous formulation of daratumumab, plus standard-of-care treatment, led to response rates that were similar to those seen with intravenous daratumumab in patients with...
Cardiovascular Events Common With Proteasome Inhibitor Therapy for Previously Treated Multiple Myeloma
Cardiovascular adverse events (CVAEs) commonly occur during proteasome inhibitor (PI) therapy for relapsed/refractory multiple myeloma (MM), particularly in patients with elevated natriuretic peptides or...
Can Immunomodulatory Drugs Overcome CHIP’s Effects in Post-Transplant Multiple Myeloma?
Patients with multiple myeloma (MM) who harbor somatic mutations in hematopoietic cells, known as clonal hematopoiesis of indeterminate potential (CHIP), have better post–autologous hematopoietic...
More Options, More Questions: Debating the Optimal Frontline Regimen for Multiple Myeloma
As part of the 2019 ASH Meeting on Hematologic Malignancies held September 6-7 in Chicago, experts were invited to discuss challenging patient care questions,...
From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
European Commission Approves Elotuzumab Triplet for Multiple Myeloma
The European Commission (EC) has approved elotuzumab plus pomalidomide and low-dose dexamethasone (EPd) to treat relapsed and refractory multiple myeloma in adult patients who...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
